AstraZeneca on Wednesday said that the company and its wholly owned subsidiary, AstraZeneca Finance LLC, priced a six- tranche global bond offering totaling seven billion dollars.
The offering is expected to close on Friday.
The transaction consists of the six tranches, with maturing date between May 28, 2024, and May 28, 2051.
AstraZeneca said it expects to use the net proceeds of the offering to fund a portion of the purchase price for the Alexion Acquisition.
It will also pay or refinance a portion of Alexion’s indebtedness and pay related fees and expenses, or for general corporate purposes, which may include the refinancing of existing indebtedness.